[go: up one dir, main page]

EA200801509A1 - Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7 - Google Patents

Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7

Info

Publication number
EA200801509A1
EA200801509A1 EA200801509A EA200801509A EA200801509A1 EA 200801509 A1 EA200801509 A1 EA 200801509A1 EA 200801509 A EA200801509 A EA 200801509A EA 200801509 A EA200801509 A EA 200801509A EA 200801509 A1 EA200801509 A1 EA 200801509A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ptk7
antibodies
methods
monoclonal antibodies
human monoclonal
Prior art date
Application number
EA200801509A
Other languages
English (en)
Other versions
EA017812B1 (ru
Inventor
Ли-шэнг Лу
Джонатан Александр Терретт
Чин Пэн
Original Assignee
Медарекс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38123515&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200801509(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Медарекс, Инк. filed Critical Медарекс, Инк.
Publication of EA200801509A1 publication Critical patent/EA200801509A1/ru
Publication of EA017812B1 publication Critical patent/EA017812B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение включает выделенные моноклональные антитела, в частности, человеческие моноклональные антитела, которые специфически связываются с РТК7 с высокой аффинностью. Также предусматриваются нуклеотидные молекулы, кодирующие антитела по изобретению, векторы экспрессии, клетки-хозяева и способы экспрессирования антител по изобретению. Также охватываются иммуноконъюгаты, биспецифические молекулы и фармацевтические композиции, содержащие антитела по изобретению. Также изобретение включает способы обнаружения РТК7 и способы лечения различных заболеваний, включая рак и инфекционные заболевания, с применением антител против РТК7.
EA200801509A 2005-12-08 2006-12-08 Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение EA017812B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74837305P 2005-12-08 2005-12-08
PCT/US2006/046837 WO2007067730A2 (en) 2005-12-08 2006-12-08 Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use

Publications (2)

Publication Number Publication Date
EA200801509A1 true EA200801509A1 (ru) 2008-12-30
EA017812B1 EA017812B1 (ru) 2013-03-29

Family

ID=38123515

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801509A EA017812B1 (ru) 2005-12-08 2006-12-08 Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение

Country Status (21)

Country Link
US (3) US8222375B2 (ru)
EP (1) EP1957539B1 (ru)
JP (1) JP5401639B2 (ru)
KR (1) KR101373464B1 (ru)
CN (1) CN101360761B (ru)
AU (1) AU2006321841C1 (ru)
BR (1) BRPI0619582A2 (ru)
CA (1) CA2632552C (ru)
DK (1) DK1957539T3 (ru)
EA (1) EA017812B1 (ru)
ES (1) ES2406063T3 (ru)
IL (1) IL191788A (ru)
ME (1) ME02002B (ru)
NO (1) NO20082559L (ru)
NZ (2) NZ569236A (ru)
PL (1) PL1957539T3 (ru)
PT (1) PT1957539E (ru)
RS (1) RS52804B (ru)
SG (1) SG177194A1 (ru)
SI (1) SI1957539T1 (ru)
WO (1) WO2007067730A2 (ru)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067730A2 (en) 2005-12-08 2007-06-14 Medarex, Inc. Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
SG170080A1 (en) * 2005-12-08 2011-04-29 Medarex Inc Human monoclonal antibodies to o8e
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
US7960125B2 (en) * 2007-09-25 2011-06-14 The Board Of Trustees Of The Leland Stanford Junior University Identification of thymically derived CD4 T cells by protein tyrosine kinase 7 expression
AU2008323848B2 (en) 2007-11-07 2014-09-25 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
JP2011505146A (ja) * 2007-11-30 2011-02-24 ブリストル−マイヤーズ スクイブ カンパニー タンパク質チロシンキナーゼ７（ｐｔｋ７）を対象とするモノクローナル抗体−パートナー分子複合体
KR101123130B1 (ko) * 2008-03-17 2012-03-30 연세대학교 산학협력단 Ｐｔｋ７ 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제
WO2009116764A2 (ko) * 2008-03-17 2009-09-24 연세대학교 산학협력단 Ptk7 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제
EP2451844B1 (en) 2009-07-10 2015-04-22 Innate Pharma Tlr3 binding agents
US8394922B2 (en) * 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
EP2380909A1 (en) * 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PTK-7 protein involved in breast cancer
WO2011146313A1 (en) 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
SA112330278B1 (ar) * 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
BR112014007788A2 (pt) 2011-10-03 2017-04-18 Univ North Carolina Chapel Hill compostos de pirrolopirimidina para tratamento do câncer
SG11201404667XA (en) 2012-02-13 2014-09-26 Bristol Myers Squibb Co Enediyne compounds, conjugates thereof, and uses and methods therefor
AU2013266438B2 (en) 2012-05-22 2017-09-07 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
US9944712B2 (en) 2012-05-31 2018-04-17 Innate Pharma TLR3 binding agents
EP2909211A4 (en) 2012-10-17 2016-06-22 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
US9771330B2 (en) 2012-11-27 2017-09-26 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
KR102215954B1 (ko) 2013-02-14 2021-02-15 브리스톨-마이어스 스큅 컴퍼니 튜부리신 화합물, 그의 제조 및 사용 방법
CN105899515B (zh) 2013-08-14 2020-01-14 威廉马歇莱思大学 uncialamycin的衍生物、合成方法及其作为抗肿瘤剂的用途
WO2015157125A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Therapuetic uses of selected pyrazolopyrimidine compounds with anti-mer tyrosine kinase activity
PL3137114T3 (pl) * 2014-04-30 2021-06-28 Pfizer Inc. Koniugaty przeciwciało anty-ptk7-lek
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
SMT202000579T1 (it) 2014-11-21 2020-11-10 Bristol Myers Squibb Co Anticorpi comprendenti regioni costanti pesanti modificate
WO2016115201A1 (en) 2015-01-14 2016-07-21 Bristol-Myers Squibb Company Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using
TWI732760B (zh) * 2015-05-29 2021-07-11 美商必治妥美雅史谷比公司 抗ｏｘ４０抗體及其用途
KR20180089433A (ko) 2015-12-21 2018-08-08 브리스톨-마이어스 스큅 컴퍼니 부위-특이적 접합을 위한 변이체 항체
CN108884169B (zh) 2016-01-22 2022-03-22 默沙东公司 抗凝血因子xi抗体
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
CN109069665A (zh) 2016-05-10 2018-12-21 百时美施贵宝公司 具有增强的稳定性的微管溶素类似物的抗体-药物缀合物
MA45234A (fr) 2016-06-14 2019-04-17 Adimab Llc Anticorps anti-facteur xi de coagulation
KR102493853B1 (ko) 2016-08-19 2023-01-30 브리스톨-마이어스 스큅 컴퍼니 세코-시클로프로파피롤로인돌 화합물, 그의 항체-약물 접합체, 및 제조 및 사용 방법
US10398783B2 (en) 2016-10-20 2019-09-03 Bristol-Myers Squibb Company Antiproliferative compounds and conjugates made therefrom
CA3044682A1 (en) 2016-12-02 2018-06-07 University Of Southern California Synthetic immune receptors and methods of use thereof
SG10201913206RA (en) 2017-05-25 2020-02-27 Bristol Myers Squibb Co Antibodies comprising modified heavy constant regions
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US11485741B2 (en) 2018-04-24 2022-11-01 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (TLR7) agonists
IL317033A (en) 2018-05-29 2025-01-01 Bristol Myers Squibb Co Modified atomic groups that lend themselves to use in prodrugs and conjugates and methods for use and preparation
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
KR20210092236A (ko) * 2018-11-07 2021-07-23 크리스퍼 테라퓨틱스 아게 항-ptk7 면역세포 암 치료법
CN113348177A (zh) 2018-11-28 2021-09-03 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
CN113453725A (zh) 2018-11-30 2021-09-28 百时美施贵宝公司 包含含有谷氨酰胺的轻链c末端延伸的抗体、其缀合物以及方法和用途
JP7514836B2 (ja) 2018-12-12 2024-07-11 ブリストル－マイヤーズ スクイブ カンパニー トランスグルタミナーゼによるコンジュゲーションのための改変抗体、ならびにそのコンジュゲート、方法および用途
KR102236127B1 (ko) 2019-08-08 2021-04-07 주식회사 하울바이오 티로시나아제를 억제하는 항-티로시나아제 항체 및 이의 용도
WO2021055306A1 (en) 2019-09-16 2021-03-25 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
TW202208412A (zh) * 2020-05-06 2022-03-01 瑞士商Ｃｒｉｓｐｒ治療公司 對酪胺酸蛋白激酶樣７（ｐｔｋ７）特異的經掩蔽的嵌合抗原受體和表現其的免疫細胞
WO2022015113A1 (ko) * 2020-07-16 2022-01-20 연세대학교 산학협력단 Ptk7에 특이적으로 결합하는 항체 및 이의 용도
CN115894696A (zh) * 2021-08-18 2023-04-04 和迈生物科技有限公司 抗ptk7单域抗体及其应用
CN114213541B (zh) * 2021-12-20 2022-12-30 南京诺唯赞生物科技股份有限公司 一种全能核酸酶的单克隆抗体及其制备方法
JP2025510623A (ja) 2022-03-23 2025-04-15 シンアフィックス ビー．ブイ． Ｐｔｋ７を発現する腫瘍を標的化するための抗体コンジュゲート
KR20250012620A (ko) * 2022-05-19 2025-01-24 마이틱 테라퓨틱스, 인크. Ph 의존적으로 결합하는 ptk7-결합 단백질 및 이의 용도
GB202209196D0 (en) * 2022-06-22 2022-08-10 Almac Discovery Ltd Bi-specific antigen binding molecules
EP4573129A1 (en) * 2022-08-19 2025-06-25 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Ptk7-binding protein and use thereof
WO2024054030A1 (ko) * 2022-09-06 2024-03-14 연세대학교 산학협력단 항-ptk7 항체 및 이의 용도
JPWO2024080325A1 (ru) * 2022-10-14 2024-04-18
WO2024193679A1 (en) * 2023-03-23 2024-09-26 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Antibodies and uses thereof
CN118852442A (zh) * 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
WO2025117639A1 (en) * 2023-11-27 2025-06-05 Profoundbio Us Co. Antibodies and methods for ptk7 detection
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708930A (en) * 1984-11-09 1987-11-24 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
WO1996037610A2 (en) 1995-05-25 1996-11-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders
JPH11513391A (ja) 1995-10-03 1999-11-16 ザ スクリップス リサーチ インスティテュート Ｃｃ−１０６５ 及びズオカーマイシンのｃｂｉ 類縁体
AU6887698A (en) 1997-04-08 1998-10-30 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
WO1998052925A1 (en) 1997-05-22 1998-11-26 The Scripps Research Institute Analogs of duocarmycin and cc-1065
KR20020047098A (ko) 1999-07-29 2002-06-21 추후제출 ＨＥＲ2/ｎｅｕ에 대한 인간 모노클로날 항체
CA2440703A1 (en) 2001-01-24 2002-08-01 Protein Design Labs, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
AU2002309583A1 (en) 2001-04-18 2002-11-05 Protein Desing Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
KR20030033007A (ko) 2001-05-31 2003-04-26 코울터 파머수티컬, 인코포레이티드 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제
GB0114033D0 (en) 2001-06-09 2001-08-01 Innovata Biomed Ltd Process
JP4541693B2 (ja) 2001-06-11 2010-09-08 メダレックス，インコーポレイティド Ｃｄ１０活性化プロドラッグ化合物
AU2002345673B2 (en) 2001-06-13 2007-04-26 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
WO2003022806A2 (en) 2001-09-07 2003-03-20 The Scripps Research Institute Cbi analogues of cc-1065 and the duocarmycins
JP2003088388A (ja) 2001-09-14 2003-03-25 Herikkusu Kenkyusho:Kk 新規な全長ｃＤＮＡ
EP1434881A4 (en) 2001-09-17 2005-10-26 Protein Design Labs Inc METHOD FOR DIAGNOSIS OF CANCER COMPOSITIONS AND METHOD FOR SCREENING ON CANCER MODULATORS
AU2002362646A1 (en) 2001-10-09 2003-04-22 The Johns Hopkins University A phosphatase associated with metastasis
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
CA2471645A1 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
PT1461359E (pt) * 2002-01-18 2007-06-29 Pf Medicament Anticorpos anti-igf-ir e suas aplicações
AU2003253880A1 (en) 2002-07-15 2004-02-02 Sugen, Inc. Novel kinases
GB0219776D0 (en) 2002-08-24 2002-10-02 Oxford Glycosciences Uk Ltd A protein involved in carcinoma
KR100818689B1 (ko) 2003-03-10 2008-04-02 도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 간엽계 간세포의 식별방법
EP1639090A4 (en) 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
WO2005063987A1 (en) 2003-12-19 2005-07-14 Aveo Pharmaceuticals, Inc. Gp153: methods and compositions for treating cancer
WO2005117941A2 (en) 2004-04-29 2005-12-15 Genzyme Corporation Methods and compositions for the treatment of polycystic diseases
NZ550934A (en) 2004-05-19 2010-05-28 Medarex Inc Chemical linkers and conjugates thereof
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
WO2006002203A2 (en) 2004-06-23 2006-01-05 Genzyme Corporation Methods and compositions for the treatment of polycystic diseases
WO2006110593A2 (en) 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
ES2416136T3 (es) 2005-09-26 2013-07-30 Medarex, Inc. Conjugados de anticuerpo-fármaco y su uso
WO2007067730A2 (en) 2005-12-08 2007-06-14 Medarex, Inc. Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
JP2011505146A (ja) 2007-11-30 2011-02-24 ブリストル−マイヤーズ スクイブ カンパニー タンパク質チロシンキナーゼ７（ｐｔｋ７）を対象とするモノクローナル抗体−パートナー分子複合体
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos

Also Published As

Publication number Publication date
US8222375B2 (en) 2012-07-17
AU2006321841A1 (en) 2007-06-14
US20100034826A1 (en) 2010-02-11
WO2007067730A3 (en) 2007-11-01
JP5401639B2 (ja) 2014-01-29
BRPI0619582A2 (pt) 2012-12-11
PT1957539E (pt) 2013-06-25
CN101360761B (zh) 2012-09-12
ME02002B (me) 2013-10-31
SI1957539T1 (sl) 2013-05-31
EA017812B1 (ru) 2013-03-29
CA2632552A1 (en) 2007-06-14
NZ569236A (en) 2012-06-29
SG177194A1 (en) 2012-01-30
IL191788A0 (en) 2009-02-11
ES2406063T3 (es) 2013-06-05
US9102738B2 (en) 2015-08-11
KR101373464B1 (ko) 2014-03-14
IL191788A (en) 2014-06-30
AU2006321841B2 (en) 2012-08-30
WO2007067730A2 (en) 2007-06-14
DK1957539T3 (da) 2013-05-06
RS52804B (en) 2013-10-31
EP1957539A2 (en) 2008-08-20
NO20082559L (no) 2008-07-07
AU2006321841C1 (en) 2013-01-24
US20120207764A1 (en) 2012-08-16
CN101360761A (zh) 2009-02-04
HK1121174A1 (en) 2009-04-17
KR20080082660A (ko) 2008-09-11
US20120219557A1 (en) 2012-08-30
NZ594466A (en) 2012-08-31
US9505845B2 (en) 2016-11-29
CA2632552C (en) 2015-02-03
PL1957539T3 (pl) 2013-08-30
JP2009518039A (ja) 2009-05-07
EP1957539B1 (en) 2013-04-17

Similar Documents

Publication Publication Date Title
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
EA200870021A1 (ru) Человеческие моноклональные антитела к фукозил-gm1 и способы применения анти-фукозил-gm1 антител
EA200870020A1 (ru) Человеческие моноклональные антитела против о8е
EA200800953A1 (ru) Человеческие моноклональные антитела к cd70
EA200800229A1 (ru) Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1)
EA200800094A1 (ru) Антитела cd19 и их использование
MX2009005189A (es) Anticuerpos humanos monoclonales para btla y metodos de uso.
MX2009003306A (es) Anticuerpos humanos que se unen a cxcr4 y sus usos.
MY150246A (en) Alpha 5 - beta 1 antibodies and their uses
WO2006089230A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
MX2010005830A (es) Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
NO20064866L (no) IRTA-5 antistoffer og deres anvendelse
CY1117236T1 (el) Μονοκλωνικα αντισωματα εναντι γλυπικανης-3
TW200716743A (en) Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
MX2009006277A (es) Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
TW200635946A (en) Binding proteins specific for human matriptase
WO2006116192A3 (en) Irta-1 antibodies and their uses
WO2006039135A3 (en) Irta-4 antibodies and their uses
CY1114151T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα ως προς την κιναση τυροσινης πρωτεϊνης 7 (ρτκ7) και η χρηση αυτων
CY1113958T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα σε φουκοζυλ-gμ1 και μεθοδοι για τη χρηση αντι-φουκοζυλ-gμ1
CY1116843T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα προς συνδετη 1 προγραμματισμενου θανατου (pd-l1)

Legal Events

Date Code Title Description
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU